Andrew Hedin is a Partner at Bessemer Venture Partners, where he leads biotech and techbio investing, focusing on AI-enabled therapeutics, novel modalities, and the intersection of software and life sciences. In addition to Peptone’s board, he has been a board member for companies including Kymera Therapeutics, Seismic Therapeutic, Soufflé Therapeutics, TRIANA Biomedicines, Converge Bio and Plenful.
Before Bessemer, Andrew invested in biotechnology and healthcare at F-Prime Capital and advised biopharma clients at Leerink Partners. He holds an MBA from Wharton and studied the biological basis of behavior at the University of Pennsylvania.